We have studied the pharmacokinetics of a single bolus dose of tramadol 2 mg kg -1 injected either i.v. or into the caudal epidural space in 14 healthy children, aged 1-12 yr, undergoing elective limb, urogenital or thoracic surgery. Serum concentrations of tramadol and its metabolite O-demethyl tramadol (M1) were measured in venous blood samples at various intervals up to 20 h by non-stereoselective gas chromatography with nitrogen-selective detection. All pharmacokinetic variables were evaluated using a non-compartmental model. After a single i.v. injection (nϭ9), the mean elimination half-life of tramadol was 6.4 (SD 2.7) h, with a volume of distribution of 3.1 (1.1) litre kg -1 and total plasma clearance of 6.1 (2.5) ml kg -1 min -1 . All of these pharmacokinetic variables were similar to those reported previously in adults. After caudal epidural administration (nϭ5), mean elimination half-life was 3.7 (0.9) h, volume of distribution was 2.0 (0.4) litre kg -1 and total clearance was 6.6 (1.9) ml kg -1 min -1 . The caudal/i.v. quotient of the AUC was 0.83, which confirms that there is extensive systemic absorption of tramadol after caudal administration. Serum concentrations of M1 showed a time course typical of a metabolite after both modes of administration. Serum concentrations of M1 after caudal administration were lower than those after i.v. injection.
Tramadol is a centrally acting analgesic which has been metabolites. Of all the metabolites, O-demethyl tramadol licensed for use in children older than 12 yr in the UK (M1) is the only active metabolite 10 with a greater affinity since 1994, although it has been licensed in children older for the µ receptor than the parent compound. 11 than 1 yr of age in many other European countries since
Although the pharmacokinetics of tramadol in adults 1977. It acts at opioid receptors and also appears to modify after i.v. and enteral administration have been studied, 12 13 transmission of pain impulses by inhibition of monoamine there are no comparative data in children. Therefore, we reuptake. 1 Tramadol is a racemic mixture of two enanti-have investigated the pharmacokinetics of a single bolus omers. The (ϩ)-enantiomer has a moderate affinity for the dose of tramadol 2 mg kg -1 injected either i.v. or into the opioid µ receptor, greater than that of the (-)-enantiomer. caudal epidural space in children. In addition, the (ϩ)-enantiomer inhibits serotonin reuptake and the (-)-enantiomer is a norepinephrine reuptake inhib-Patients and methods itor. These complementary properties result in a synergistic After obtaining approval from the Local Ethics committee antinociceptive interaction between the two enantiomers. 1 and written, informed parental consent, we studied 14 The result is an opioid with a striking lack of respiratory healthy children, ASA I and II, aged 1-12 yr, undergoing depressant effect despite an analgesic potency approxielective surgery. Nine children requiring limb and thoracic mately equal to that of pethidine. 2-4 Furthermore, animal surgery were given a single i.v. injection of tramadol and work has suggested that tramadol may have a selective spinal five children requiring urogenital surgery were given a action. 5 Tramadol has been shown to provide effective, single injection of tramadol into the caudal epidural space. long-lasting analgesia after epidural administration in both Children were excluded if they were undergoing day-case adults 6 7 and children. 8 9 In addition, biotransformation of tramadol in the liver results in many phase I and II surgery or were receiving concurrent medications.
No premedication was given. EMLA cream (Astra UK 8.4% for M1. Checks were made to ensure that lidocaine, thiopental, morphine, diclofenac and paracetamol did not Ltd) was applied over two visible veins 1-1.5 h before surgery. On arrival in the anaesthetic room, i.v. cannulation interfere with the non-stereoselective assay method.
The pharmacokinetic evaluation was performed using the was performed and anaesthesia was induced with thiopental 5 mg kg -1 . In four patients, neuromuscular block was model-independent method, with the software program MODINDEP developed by the Department of Pharmacoachieved with atracurium 0.5 mg kg -1 for facilitation of tracheal intubation, while in other children (nϭ10) a laryn-kinetics of Grunenthal GmbH and validated with the noncompartmental part of TOPFIT 2.0. 15 Peak serum concentrageal mask airway was inserted. Anaesthesia was maintained with an end-tidal isoflurane concentration of 0.5-1% and tions (C P max), time to peak concentrations (tC P max) and area under the serum concentration curve (AUC) were 66% nitrous oxide in oxygen. A second large i.v. cannula (20-gauge) was inserted into a long saphenous vein at derived from individual concentration-time courses. The elimination half-life (T 1/2 β ), total clearance (Cl tot ), volume the ankle to facilitate subsequent blood sampling. Before surgery, i.v. injection of tramadol (Zydol, Searle UK Ltd) of distribution (Vd β ) and mean residence time (MRT) were calculated using standard formulae. 16 2 mg kg -1 diluted in 0.9% saline 10 ml was given over 30 s via the cannula in the hand to those children undergoing All values are expressed as mean (SD). Patient characteristics in both groups were compared using an unpaired t limb or thoracic surgery (nϭ9). For those children undergoing hypospadias repair (nϭ5), an injection of tramadol test (SPSS, UK Ltd). A probability of Ͻ5% was considered statistically significant. 2 mg kg -1 , diluted with 0.9% saline to a total volume of 0.75 ml kg -1 , was given into the caudal epidural space.
During and after operation, rescue analgesia was provided Results using i.v. morphine, rectal diclofenac or oral paracetamol, Patient characteristics and pharmacokinetic variables for as indicated clinically.
those who received i.v. and caudal tramadol are shown in For subsequent evaluation of serum concentrations of Table 1 . The median age of children in the i.v. group was tramadol and its metabolite M1, 2-ml blood samples were 2.42 (range 1.17-6.58) yr, which was significantly different obtained from the indwelling venous cannula at regular from that in the caudal group (median age 6.0 (5.5-12) yr). time intervals after injection of drug. In the i.v. group, blood samples were obtained at 10, 20, 30, 45 and 60 min Tramadol and at 2, 3, 4, 6, 8, 10, 12, 16 and 20 h after injection. In After i.v. injection, the serum concentration decay curve the caudal group, blood samples were obtained at 15, 30, followed a biexponential pattern with a highest mean 45 and 60 min and at 1.5, 2, 3, 4, 6, 8, 10, 12, 16 and 20 h concentration of 1079 (SD 442) ng ml -1 at 0.19 (0.06) h after injection of tramadol. The samples were centrifuged, (Fig. 1) . After caudal administration, the time course of the serum separated and stored at -20°C until assay. Serum mean serum tramadol concentrations was characterized by concentrations of tramadol and its metabolite M1 were a peak of 709 (259) ng ml -1 at 0.5 (0.11) h (Fig. 1 ). At measured simultaneously by non-stereoselective gas chro-4 h after i.v. injection, mean serum concentration was 369 matography with nitrogen-selective detection. 14 Diazo-(133) ng ml -1 , whereas a mean concentration of 411 (106) ethane was used as the derivatization agent for M1. The ng ml -1 was obtained after caudal administration. calibration curves with sample concentrations of 2.5-500 ng ml -1 for tramadol and 2-200 ng ml -1 for M1 were linear,
O-demethyl tramadol (M1)
with a coefficient of correlation greater than 0.997. The precision and accuracy of the assay were high with a After i.v. injection, the metabolite M1 had a mean peak serum concentration of 63.9 (30.7) ng ml -1 at 4.9 (1.9) h coefficient of variation of 4.2-8.4% for tramadol and 2.9- (Fig. 2) . After caudal administration, the peak value (40.3 significance. 17 In addition, the inter-individual variability of (ϩ)-tramadol/total tramadol and (ϩ)-M1/total M1 ratios (4.3) ng ml -1 ) of M1 was observed at 6.4 (1.5) h (Fig. 2) .
are low (cv Ͻ5%) (data on file at Grunenthal GmbH). Moreover, pilot experiments using stereoselective analytical Discussion methods have shown that the same is true for the pharmacoWe found that mean serum concentrations of tramadol and kinetics of tramadol and M1 in children (data on file at its metabolite M1 after a single i.v. injection of tramadol Grunenthal GmbH). Hence application of a non-selective were only slightly higher than those in adults. 12 Similarly, analytical method in the present study was justified. none of the pharmacokinetic variables calculated was
In view of the differences in age and weight, it may be significantly different from those reported previously in that they were different populations. In addition, the two healthy adults. 12 In our study, tramadol had a mean Vd β of different anaesthetic techniques would have affected blood 3.1 (1.1) litre kg -1 , which agrees with a value of 2.74 (0.54) flow to the various compartments and some of the pharmacolitre kg -1 in adults. 12 Mean elimination half-life was 6.4 kinetic data. Hence comparison of the two groups is not (2.7) h and mean total plasma clearance 6.1 (2.5) ml min -1 possible. In our study, peak serum concentrations of tramakg -1 , which are comparable with values of 5.1 (0.8) h and dol were observed at 0.55 (0.11) h after caudal administra-6.31 (1.68) ml min -1 kg -1 , respectively, in healthy adult tion whereas maximum serum concentrations after i.m. volunteers. 12 13 Thus our results give no indication of any injection in healthy adults occurred at 0.75 (0.38) h. 18 These clinically significant difference in the pharmacokinetics of data would suggest that there is more rapid transfer of tramadol between children (1-12 yr) and adults after i.v. tramadol to the systemic circulation after caudal administrainjection. It would appear, therefore, that on the basis of tion than after i.m. administration. Moreover, in our study, the pharmacokinetic data available at present, children the mean AUC after caudal administration was only 17% require the same body weight related doses as adults. We lower than that after i.v. injection, confirming that there is cannot compare our results from children given a caudal extensive systemic absorption of tramadol after caudal epidural injection of tramadol with those in adults, as no administration. An exact value for the extent of systemic pertinent data are available.
bioavailability after epidural administration cannot be deterAlthough tramadol is a racemic mixture of two enanti-mined because the data for the two modes of administration omers, 1 stereoselective analytical methods in adults have were obtained from two different subject groups. Hence demonstrated that the pharmacokinetic differences between analgesia that is produced after epidural injection may be the enantiomers of tramadol and its metabolite are of minor attributable to systemic availability alone. The significant delay in onset time for analgesic effect after caudal administration, demonstrated in clinical studies, 8 is in accordance with the fact that peak serum concentrations are reached significantly later after caudal epidural than after i.v. injection. We hypothesize that tramadol, injected into the epidural space, has a prolonged duration of action because of sustained release of drug from epidural fat and other relatively poorly perfused tissues.
Recently published results suggest that the metabolite M1 has a T 1/2 β of 6-7 h in healthy adult volunteers 13 and contributes to the analgesic effect of the parent drug. 19 As O-demethylation of tramadol is carried out by cytochrome adult levels by 1 yr of age, 21 22 it is not surprising that the M1/tramadol serum concentration ratio after i.v. injection we found in children was similar to that reported previously in adults. 13 In summary, we believe that there is no logical reason to inject tramadol into the epidural space. Injection of tramadol into the epidural space appears to act only as a depot for immediate and delayed systemic absorption. Administration by other enteral and parenteral routes is equally efficacious and long lasting, particularly if repeated doses are given. We believe that further pharmacokinetic studies of tramadol in children examining blood concentrations after repeat i.v. or oral administration would be jus- tified.
